Titanium-nitride-oxide-coated Titan-2 bioactive coronary stent: a new horizon for coronary intervention.
The introduction of drug-eluting stents has revolutionized the field of interventional cardiology, since it has reduced the incidence of restenosis by 50-70%. However, recent worrisome data from registries and meta-analyses emphasized higher rates of late and very late stent thrombosis associated with drug-eluting stents. The recently introduced titanium-nitride-oxide-coated stent (Titan-2) has demonstrated an excellent biocompatibility, as reflected by lower rates of platelet aggregation and fibrin deposition, and better endothelialization. Preclinical and clinical trials and registries involving both real-life unselected populations and populations with the most challenging patient and lesion characteristics have shown a low rate of major adverse cardiac events in the long-term, with a restenosis rate comparable with that of drug-eluting stents, with the virtual absence of stent thrombosis.
Karjalainen
Pasi P
PP
Department of Cardiology, Satakunta Central Hospital, Pori, Finland. pasi.karjalainen@satshp.fi
Ylitalo
Antti
A
Airaksinen
Juhani K E
JK
Nammas
Wail
W
D002986:Clinical Trials as Topic; D020099:Coated Materials, Biocompatible / Q000627:therapeutic use*; D023903:Coronary Restenosis / Q000628:therapy*; D006801:Humans; D015607:Stents / Q000009:adverse effects; D014025:Titanium / Q000009:adverse effects / Q000627:therapeutic use*
D020099:Coated Materials, Biocompatible; C434243:titanium-nitride-oxide; D014025:Titanium